- July 26, 2026
Point-of-Care Drug Testing: How Rapid Drug Screening Works
A simple guide to how point-of-care drug screening works, when it is used and why results may require laboratory confirmation.
Point-of-Care Drug Testing: How Rapid Drug Screening Works
Point-of-care drug testing provides a rapid indication of whether selected drugs or drug metabolites may be present in a sample. It can be used in workplace, healthcare, occupational health, rehabilitation and safety-critical settings where timely screening information is required.
Unlike testing that is performed entirely within a laboratory, point-of-care testing takes place close to the person being tested. It may use a urine drug testing cup, test cassette, dip card or oral-fluid testing device. Results are often available within minutes, although the precise reading time depends on the individual product instructions.
What is point-of-care drug testing?
Point-of-care drug testing is an initial screening method performed outside a traditional laboratory environment. The test device is designed to detect selected drugs or drug metabolites at specified cut-off concentrations.
Common specimens include urine and oral fluid. Other specimen types can also be used for drug testing, depending on the testing purpose and the procedures being followed. SAMHSA
The result is normally qualitative. This means the test indicates whether the relevant substance has or has not been detected at or above the product’s cut-off level. It does not usually provide the exact concentration present in the sample.
For organisations seeking a practical urine-screening format, Virex Diagnostics supplies professional multi-panel urine drug testing cups.
[INTERNAL LINK: Link the words “multi-panel urine drug testing cups” to the Virex Drug Cup product page.]
How does rapid drug screening work?
Many rapid drug-screening devices use immunoassay technology. These tests use chemical reactions designed to identify particular drug groups or their metabolites. Immunoassays are commonly used for initial screening because they can quickly identify samples that may require further investigation, but they are not sufficiently specific to replace confirmatory analysis where confirmation is required. SAMHSA
A typical point-of-care urine testing process involves:
- Collecting the urine sample.
- Securing or activating the testing device as instructed.
- Waiting for the stated development period.
- Checking that the control indicator has appeared.
- Reading the result within the timeframe specified by the manufacturer.
- Recording and managing the result according to the organisation’s procedure.
Some urine testing cups include a temperature strip. When checked within the period specified in the product instructions, this can provide additional information about the specimen at the point of collection. Selected devices may also contain additional specimen-integrity checks.
[INTERNAL LINK: Link “specimen-integrity checks” to the Available Variants or Specifications section of the Virex Drug Cup page.]
What do negative and non-negative results mean?
A negative result means the test has not detected the relevant drug or metabolite at or above the stated cut-off level.
A non-negative result means the screening device has indicated the possible presence of a relevant substance at or above its cut-off. It should not automatically be treated as proof of misuse, impairment or a final confirmed finding.
Drug screening indicates whether a target substance may be present within the limits of the test. It does not, by itself, determine when a drug was taken, how much was consumed or whether the individual was impaired at a particular time.
Benefits of point-of-care drug testing
Rapid initial results
Point-of-care testing can produce an initial screening result within a relatively short period, helping organisations determine whether further action or analysis may be appropriate.
Practical on-site use
The test can be performed at the collection location, reducing the need to send every specimen to a laboratory for the initial screening stage.
Multiple panel configurations
Testing products can be configured to screen for different combinations of drugs or drug groups. The appropriate panel should be selected according to the purpose of testing, the organisation’s policy and the substances of concern.
[INTERNAL LINK: Link “appropriate panel” to the blog titled “How to Choose the Right Drug Testing Panel for Your Organisation”.]
Support for further investigation
Rapid screening can help identify samples that may require independent laboratory confirmation or further professional review.
What are the limitations?
Point-of-care tests are preliminary screening tools. Like all testing methods, they must be used correctly and interpreted within their intended purpose and limitations.
Factors that may affect the reliability of a testing process include:
- Using an unsuitable drug panel
- Reading the device too early or too late
- Incorrect sample collection or handling
- Failure to follow the manufacturer’s instructions
- Cross-reactivity during immunoassay screening
- Inadequate documentation or result-management procedures
The FDA also advises that a preliminary drug-test result should be followed by a more specific laboratory test where a test indicates the possible presence of a drug and a final result is required. U.S. Food and Drug Administration
When may laboratory confirmation be required?
Laboratory confirmation may be appropriate where:
- A screening result is non-negative
- The result is disputed
- A significant decision may be based on the result
- The organisation’s policy requires confirmation
- A more specific identification of a drug or metabolite is needed
- The result may be used in a disciplinary, safeguarding or legally sensitive process
[INTERNAL LINK: Link “laboratory confirmation” to the Laboratory Confirmation Services page.]
Confirmation testing generally uses an analytical method combining chromatographic separation with mass-spectrometric identification. This provides greater analytical specificity than an initial immunoassay screen. SAMHSA
For further information about good practice in workplace testing, organisations can review the European Workplace Drug Testing Society’s guidance resources.
[EXTERNAL LINK: Link “European Workplace Drug Testing Society’s guidance resources” to the EWDTS Guidelines page.]
Why a clear testing procedure matters
A reliable testing process involves more than choosing a suitable test device. Organisations should also consider:
- Who is authorised and competent to conduct testing
- How consent will be obtained
- How specimens will be collected and handled
- How results will be recorded
- When laboratory confirmation will be arranged
- How confidentiality will be protected
- What actions may follow each type of result
The Health and Safety Executive advises that workplace screening should form part of a wider health and safety policy and that procedures must be carried out properly to reduce the risk of contamination, tampering or inaccurate analysis. HSE
[EXTERNAL LINK: Link “Health and Safety Executive guidance on screening and testing” to the HSE Screening and Testing page.]
Final thoughts
Point-of-care drug testing can provide organisations with a practical and efficient method of initial drug screening. It can support timely decision-making and identify circumstances in which further investigation may be needed.
However, a rapid test should be used as one part of a properly managed testing process. Appropriate product selection, correct collection procedures, trained personnel, clear policies and laboratory confirmation where required all contribute to more reliable and defensible testing.
This article provides general information and does not replace product instructions, legal advice, occupational-health advice or an organisation’s own testing policy.
Popular Posts
Need support choosing a point-of-care drug test?
Contact Virex Diagnostics for guidance on urine drug testing cups, drug-panel options and professional testing requirements.